Can low-grade metabolic inflammation cause low energy?

Low-grade metabolic inflammation, or "metaflammation," is characterized by chronically elevated systemic cytokines that directly impair cellular metabolic efficiency. This persistent, subclinical inflammatory state disrupts systemic glucose regulation, driving a cellular energy crisis that clinically presents as profound physical and mental fatigue.

Mechanistic explanations

• Disrupted Insulin Signaling: Pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), activate the intracellular IKKβ/NF-κB pathway. This activation triggers inhibitory serine phosphorylation of insulin receptor substrate 1 (IRS-1), blunting downstream IRS-1/PI3K/Akt signaling cascades.
• Impaired Glucose Handling: This signaling blockade prevents the translocation of glucose transporters to the cell membrane, restricting vital glucose uptake in key metabolic tissues such as skeletal muscle and brain astrocytes.
• Mitochondrial Dysfunction and ATP Deficit: The resulting reduction in cellular glucose availability, paired with cytokine-induced mitochondrial impairment, suppresses mitochondrial respiration and cellular adenosine triphosphate (ATP) production. To compensate, cells transition from highly efficient oxidative phosphorylation to less efficient aerobic glycolysis, failing to meet physiological energy demands.

Clinical implications

• Fatigue and Energy Crashes: At the systemic level, this intracellular energy deficit and reduced ATP availability manifest clinically as persistent subjective fatigue, postprandial energy crashes, cognitive difficulties, and reduced physical stamina.

Bottom line

• Low-grade metabolic inflammation directly impairs insulin signaling and glucose handling via cytokine-mediated disruption of the IRS-1 pathway, leading to mitochondrial dysfunction, reduced ATP production, and systemic physical and mental fatigue.